KiraGen Bio

Empowering solid tumor immunotherapies with TME resistance via AI-driven, multiplex gene editing.

[Aaron Edwards @aedwards02]

This is why we built @KiraGenBio.

Base editing made CAR-T possible for patients like Alyssa, CURED of T-cell leukemia after every other option failed. We built the U.S. version at @BeamTx.

Help us make more stories like Alyssa’s for patients with GBM and other solid tumors!

[Aaron Edwards @aedwards02]

Big night for @KiraGenBio — won one of 5 @IgniteLC Golden Tickets on my 36th bday.

$50K lab space + fellowship to advance our work in GBM and other solid tumors!

Grateful to @LabCentral & sponsors @Bayer, @TakedaPharma, @EliLillyandCo, and @pfizer.

[KiraGen Bio @KiraGenBio]

Our new website is live 🚀

KiraGen Bio is advancing multiplex-edited, off-the-shelf cell therapies designed to block tumor suppression signals and bring durable treatments to solid tumors.

Explore more → https://t.co/CBqPcLv2q9

[Aaron Edwards @aedwards02]

Meet the newest member of Team @KiraGenBio — our CAR-T cell mascot 🎧

Outfitted with AI-powered, noise-canceling headphones (our multiplex gene edits), it’s built to block out the solid tumor suppressive “noise” & keep fighting on!

Designed to cure. Built to endure.

[KiraGen Bio @KiraGenBio]

Our TME-Guards are like noise-cancelling headphones for CAR-T cells — silencing the suppressive signals of the tumor microenvironment so they can do their job.

[KiraGen Bio @KiraGenBio]

We are honored to be part of the inaugural AI BioHub from @c10labs & @LabCentral—bringing AI and biology together to accelerate the future of drug development.

[Aaron Edwards @aedwards02]

Excited to share that @KiraGenBio has been selected to join the inaugural AI BioHub from @c10labs & @LabCentral!

We’re building multiplex-edited CAR-T therapies guided by AI—and thrilled to be part of a cohort pushing the future of #TechBio forward.

🔗https://t.co/uz18yuuSCL

[KiraGen Bio @KiraGenBio]

Our CEO @aedwards02 joined @jonchee_excedr on @Excedr’s Biotech Startups Podcast 🎙️

In Part 1 of 4, he shares how early wonder, queerness, & a few real-life “Ms. Frizzles” helped shape his path—and KiraGen’s mission to conquer the TME.

[Excedr @ExcedrInc]

"What you don't want to do is just as important as learning what you might want to do when you grow up."

[KiraGen Bio @KiraGenBio]

🚀 Big news! KiraGen Bio is a Boston Regional Finalist in the @HarvardHBS New Venture Competition – Alumni Track!

This is a huge milestone for our AI-driven CAR-T therapies tackling solid tumors like GBM.

Next stop: Global Finals for a chance at $75K!

Onwards and Upwards! 🏆

[KiraGen Bio @KiraGenBio]

What if you could address the fundamental barriers to cell therapy effectiveness in solid tumors, rather than merely mitigating secondary functional impairments?

[KiraGen Bio @KiraGenBio]

What if you could target the root cause of cell therapy's limited success in solid tumors—the diverse immunosuppressive mechanisms within the tumor microenvironment (TME)?